Drug Trial Radar · NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
930
Planned (sponsor's estimate)
Start
Dec 8, 2021
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Relay Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).
Conditions
- PIK3CA Mutation
- Solid Tumor, Adult
- HER2-negative Breast Cancer
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Unresectable Solid Tumor
Interventions
RLY-2608Drug
RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
FulvestrantDrug
500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
Palbociclib 125mgDrug
125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Ribociclib 400mgDrug
400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Ribociclib 600mgDrug
600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
PF-07220060 100mgDrug
PF-07220060 100 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
PF-07220060 300 mgDrug
PF-07220060 300 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 as a single agentTime frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months
- Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 in combination with fulvestrantTime frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months
- Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 in combination with fulvestrant and a CDK 4/6 inhibitor (palbociclib, ribociclib), and in combination with CDK4 inhibitor (PF-07220060) and fulvestrantTime frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months
- Number of patients with adverse events and serious adverse events of RLY-2608 as a single agentTime frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months
- Number of patients with adverse events and serious adverse events of RLY-2608 in combination with fulvestrantTime frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months
- Number of patients with adverse events and serious adverse events of RLY-2608 in combination with fulvestrant and a CDK 4/6 inhibitor (palbociclib, ribociclib), and in combination with CDK4 inhibitor (PF-07220060) and fulvestrantTime frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months
Locations
37 sites in 5 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona · Recruiting
University of California-San Diego
San Diego, California · Recruiting
HealthONE
Denver, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Florida Cancer Specialists
Orlando, Florida · Recruiting
Boca Raton Clinical Research (BRCR) Global
Plantation, Florida · Withdrawn
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Community Health Network
Indianapolis, Indiana · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine St. Louis
St Louis, Missouri · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
Rutgers University
New Brunswick, New Jersey · Recruiting
NYU Langone
New York, New York · Recruiting
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York · Recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
University of Utah- Huntsman Cancer Center
Salt Lake City, Utah · Recruiting
Inova Schar Cancer Center
Fairfax, Virginia · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
UW Carbone Cancer Center
Madison, Wisconsin · Recruiting
St Vincents Hospital
Sydney, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Institute Bergonié
Bordeaux, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Centre Léon Bérard
Lyon, Auvergne-Rhône-Alpes, France · Recruiting
Istituto Europeo di Oncologia IRCCS
Milan, Italy · Recruiting
Institut Catala D'Oncologia - Badalona (ICO Badalona)
Barcelona, Spain · Recruiting
START Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Vall d'Hebron Instituto de Oncologia
Barcelona, Barcelona, Spain · Recruiting
START Barcelona
Barcelona, Catalonia, Spain · Recruiting
Instituto Valenciano de Oncologia
Valencia, Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.